Skip to main content Accessibility help
×
Home
Hostname: page-component-544b6db54f-mdtzd Total loading time: 0.183 Render date: 2021-10-19T12:02:03.532Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": true, "newCiteModal": false, "newCitedByModal": true, "newEcommerce": true, "newUsageEvents": true }

Efficacy and tolerability of blonanserin in 48 patients with intractable schizophrenia

Published online by Cambridge University Press:  24 June 2014

Manabu Takaki*
Affiliation:
Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama City, Japan
Yuko Okahisa
Affiliation:
Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama City, Japan
Masafumi Kodama
Affiliation:
Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama City, Japan
Yutaka Mizuki
Affiliation:
Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama City, Japan
Shinji Sakamoto
Affiliation:
Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama City, Japan
Hiroshi Ujike
Affiliation:
Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama City, Japan
Yosuke Uchitomi
Affiliation:
Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama City, Japan
*
Manabu Takaki, MD, PhD, Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama City 700-8558, Japan. Tel: +81862357242; Fax: +81862357246; E-mail: manabuta@cc.okayama-u.ac.jp

Extract

Takaki M, Okahisa Y, Kodama M, Mizuki Y, Sakamoto S, Ujike H, Uchitomi Y. Efficacy and tolerability of blonanserin in 48 patients with intractable schizophrenia.

Background: Blonanserin is effective for the treatment of schizophrenia in Korea and Japan.

Methods: We administered blonanserin to 48 Japanese patients with schizophrenia for whom other atypical antipsychotics were not sufficiently effective or tolerated.

Results: Previous antipsychotics were replaced with blonanserin because of its effectiveness (54.2%; 26/48) or tolerability (45.8%; 22/48). Blonanserin was more effective in 65.4% (17/26) of the and better tolerated in 95.5% (21/22) of the patients. Of 48 patients, 33 continued blonanserin for 1 year. The mean Clinical Global Impression of Severity scores improved from 4.60 to 2.48. The mean Global Assessment of Functioning score improved from 29.8 to 51.7. Nineteen patients (39.6%; 19/48) had a social role. The reasons for discontinuation of blonanserin were ineffectiveness against psychosis (27.1%; 13/48) or intolerability (4.2%; 2/48). The ratio of discontinuation for intolerability versus ineffectiveness was 0.15, which was the lowest among atypical psychotics.

Conclusions: Blonanserin may be effective and safe for the treatment of intractable schizophrenia.

Type
Case Reports
Copyright
Copyright © Cambridge University Press 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Lieberman, JA, Stroup, TS, Mcevoy, JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:12091223.CrossRefGoogle ScholarPubMed
2.Deeks, ED, Keating, GM.Blonanserin: a review of its use in the management of schizophrenia. CNS Drugs 2010;24:6584.CrossRefGoogle ScholarPubMed
3.Noda, Y, Kurumiy, S, Miura, Y, Oka, M.Comparative study of 2-(4-ethyl-1-piperazinyl)-4-(fluorophenyl)-5,6,7,8,9, 10-hexahydrocycloocta[b]pyridine (AD-5423) and haloperidol for their pharmacological activities related to antipsychotic efficacy and/or adverse side-effects. J Pharmacol Exp Ther 1993;265:745751.Google ScholarPubMed
4.Oka, T, Hamamura, T, Lee, Y et al. Atypical properties of several classes of antipsychotic drugs on the basis of differential induction of Fos-like immunoreactivity in the rat brain. Life Sci 2004;76:225237.CrossRefGoogle ScholarPubMed
5.Murasaki, M.Clinical evaluation of blonanserine for schizophrenia: double-blind comparing blonanserin with haloperidol. Jpn J Clin Psychopharmacol 2007;10:20592079.Google Scholar
6.Garcia, E, Robert, M, Peris, F, Nakamura, H, Sato, N, Terazawa, Y.The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study. CNS Drugs 2009;23:615625.CrossRefGoogle ScholarPubMed
7.Yang, J, Bahk, WM, Cho, HS et al. Efficacy and tolerability of blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial. Clin Neuropharmacol 2010;33:169175.CrossRefGoogle ScholarPubMed
8.Miura, S.Effect of new-generation antipsychotics blonanserin on cognitive impairment in schizophrenia. Jpn J Clin Psychopharmacol 2008;11:315326.Google Scholar
9.Oshimo, T.Clozapine treatment and monitoring guideline in Japan. Jpn J Clin Psychopharmacol 2009;59:13751384.Google Scholar
10.Arakawa, R, Okumura, M, Ito, H et al. Positron emission tomography measurement of dopamine D2 receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia. J Clin Psychiatry 2010;71:11311137.CrossRefGoogle ScholarPubMed
11.Millan, MJ, Di Cara, B, Dekeyne, A et al. Selective blockade of dopamine D(3) versus D(2) receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis. J Neurochem 2007;100:10471061.CrossRefGoogle ScholarPubMed
12.Bombin, I, Arango, C, Mayoral, M et al. DRD3, but not COMT or DRD2, genotype affects executive functions in healthy and first-episode psychosis adolescents. Am J Med Genet B Neuropsychiatr Genet 2008;147B:873879.CrossRefGoogle ScholarPubMed
5
Cited by

Send article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Efficacy and tolerability of blonanserin in 48 patients with intractable schizophrenia
Available formats
×

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

Efficacy and tolerability of blonanserin in 48 patients with intractable schizophrenia
Available formats
×

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

Efficacy and tolerability of blonanserin in 48 patients with intractable schizophrenia
Available formats
×
×

Reply to: Submit a response

Please enter your response.

Your details

Please enter a valid email address.

Conflicting interests

Do you have any conflicting interests? *